BOLAR's GENERIC DYAZIDE ANDA WILL BE WITHDRAWN BY FDA, AGENCY NOTIFIES FIRM AUG. 28; BIOEQUIVALENCE RATING IS DOWNGRADED TO "BX" IN THE MEANTIME